Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix

Mesh Matrix Treats Hard-to-Heal Wounds

By HospiMedica International staff writers
Posted on 27 Feb 2014
Print article
Image: The MatriStem Multilayer Wound Matrix device is designed for deep, hard-to-heal wounds (Photo courtesy of ACell).
Image: The MatriStem Multilayer Wound Matrix device is designed for deep, hard-to-heal wounds (Photo courtesy of ACell).
A new multilayer matrix device accommodates moderate to heavy wound exudate and provides effective contouring functionality in wound treatment.

The MatriStem Multilayer Wound Matrix device is designed to maintain and support a healing environment through constructive tissue remodeling for both acute and chronic wounds. The device is comprised of naturally occurring urinary bladder matrix (UBM), the basement membrane of porcine urinary bladder tissue, which is disinfected, packaged, and sterilized to produce a non-cross-linked, completely resorbable, acellular extracellular matrix (ECM) scaffold that is rich with naturally occurring collagens and proteins.

UBM provides several distinguishable characteristics, including the recruitment of progenitor cells, chemotactic and mitogenic activities, and site-specific tissue remodeling. UBM also has the ability to facilitate the body’s own regenerative capabilities and help restore normal site-appropriate tissue while avoiding scar tissue formation; the ability to be used "off-the-shelf" and stored at room temperature, with an approximate two-year shelf life; and superior ease-of-use characteristics.

MatriStem is easy to prepare, apply, and fixate, and requires no special handling requirements. It is indicated for all types of wound management, including pressure ulcers, venous ulcers, diabetic ulcers, surgical wounds, trauma wounds, and the reinforcement of soft tissue where weakness exists in urological, gynecological, and gastroenterological anatomy. The MatriStem Multilayer Wound Matrix device is a product of ACell (Columbia, MD, USA), and has been approved by the US Food and Drug Administration (FDA).

“ACell has developed MatriStem Multilayer Wound Matrix to address an unmet need in the area of acute and chronic wound care management,” said Jim DeFrancesco, CEO of ACell. “The launch of this new product provides a new option for physicians treating patients suffering from deep, hard-to-heal wounds.”

Related Links:

ACell



Print article
Radcal
Barco

Channels

Critical Care

view channel
Image: Warfarin may increase the risk of dementia in certain populations (Photo courtesy of Fotolia).

Warfarin Use Can Increase Dementia Risk in AF Patients

A new study shows that atrial fibrillation (AF) patients treated over a long period of time with Warfarin experience higher rates of dementia than their counterparts. Researchers at Intermountain Medical... Read more

Women's Health

view channel

Rotating Night Shift Raises Risk of Heart Disease in Women

Switching from day to night shift work is associated with a small increased risk for coronary heart disease (CHD) among women, according to a new study. Researchers at Brigham and Women's Hospital (Boston, AM, USA), Harvard Medical School (Boston, MA, USA), and other institutions conducted a prospective cohort study... Read more

Hospital News

view channel
Image: Hollywood Presbyterian Medical Center (Photo courtesy of HPMC).

Hollywood Presbyterian Launches USD 200 Million Expansion

The 100-year-old Hollywood Presbyterian Medical Center (HPMC; Los Angeles, CA, USA) is about to kick off its USD 200 million expansion and modernization of the facility. Phase one of the expansion will... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.